Rabies virus glycoprotein expression in Drosophila S2 cells. I. Functional recombinant protein in stable co-transfected cell line

Biotechnology Journal

Volumn 2, Issue 1, 2007, Pages 102-109

  Yokomizo, Adriana Y ^a   Jorge, Soraia A C ^a   Astray, Renato M ^a   Fernandes, Irene ^a   Ribeiro, Orlando G ^a   Q Horton, Denise S P ^a   Tonso, Aldo ^b   Tordo, Noel ^c   Pereira, Carlos A ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUT PASTEUR   (France)

Author keywords

Actin promoter; Drosophila Schneider 2 cells; Heterologous protein expression; Rabies virus glycoprotein

Indexed keywords

ACTIN; ANTIBODY; COMPLEMENTARY DNA; HYGROMYCIN; MESSENGER RNA; RECOMBINANT PROTEIN; VIRUS GLYCOPROTEIN; DROSOPHILA PROTEIN; GLYCOPROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CELL GROWTH; CELL LINE; CELL LYSATE; CELL METABOLISM; CELL POPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; DROSOPHILA MELANOGASTER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABIES VIRUS; SUPERNATANT; ANIMAL; GENETICS; METABOLISM; METHODOLOGY; PROTEIN ENGINEERING;

DROSOPHILA MELANOGASTER; MUS; RABIES VIRUS;

ANIMALS; CELL LINE; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; GLYCOPROTEINS; PROTEIN ENGINEERING; RABIES VIRUS; RECOMBINANT PROTEINS; TRANSFECTION; VIRAL PROTEINS;

EID: 33847025372     PISSN: 18606768     EISSN: None     Source Type: Journal    
DOI: 10.1002/biot.200600211     Document Type: Article

References (29)

1. Wariel, M. J., Warrel, D. A., Rabies and other lyssavirus diseases, Lancet 2004, 363, 959-969.
2. Pastoret, P. P., Brochier, B., Aguilar-Setin, A., Blancou, J., Vaccination against rabies, in: Pastoret, P. P., Blancou, J., Vanner, P., Verschueren, C. (Eds.). Veterinary Vaccinology, Elsevier, Amsterdan 1997, p. 616.
3. Lodmell, D. L., Rabies DNA vaccines for protection and therapeutic treatment. Expert Opin. Investig. Drugs 1999, 8, 115-122.
4. Diogo, M. M., Ribeiro, S. C., Queiroz, J. A., Monteiro, G. A., Tordo, N., Perrin, P., Prazeres, D. M., Production, purification and analysis of an experimental DNA vaccine against rabies. J. Gene Med. 2002, 3, 577-584.
5. Yokomizo, A. Y., Antoniazzi, M. M., Galdino, P. L., Azambuja, N. Jr. et al., Rabies virus production in high vero cell density cultures on macroporous microcarriers. Biotechnol. Bioeng. 2004, 85, 506-515.
6. Bahloul, C., Taieb, D,, Diouani, M. F., Ahmed, S. B. et al., Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions. Vaccine 2006, 24, 1063-1072.
7. Rai, N., Kaushik, P, Rai, A., Development of rabies DNA vaccine using a recombinant plasmid. Acta Virol. 2005, 49, 207-210.
8. Mendonça, R. Z., Prado, J. C. M., Pereira, C A., Attachment, spreading and growth of VERO cells on microcarriers for the optimization of large scale cultures. Bioprocess Eng. 1999, 20, 565-571.
9. Rath, A., Choudhury, S., Batra, D., Kapre, S. V. et al., DNA vaccine for rabies: relevance of the trans-membrane domain of the glycoprotein in generating an antibody response. Virus Res. 2005, 113, 143-152.
10. Gaudin, Y., Folding of rabies virus glycoprotein: Epitope acquisition and interaction with endoplasmic reticulum chaperones. J. Virol. 1997, 71, 3742-3750.
11. Desmézières, E., Maillard, A. P, Gaudin, Y., Tordo, N., Perrin, P, Differential stability and fusion activity of Lyssavirus glycoprotein trimers. Virus Res. 2003, 91, 181-187.
12. NTR receptor. J. Gen. Virol. 2005, 86, 2543-2552.
13. Wiktor, T. J., Macfarlan, R. I., Reagan, K. J., Dietzschold, B. et. al., Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc. Natl. Acad. Sci. USA 1984, 81, 7194 7198.
14. Perrin, P., Thibodeau, L., Sureau, P., Rabies immunosomes (sub-unit vaccine) structure and immunogenicity. Pre- and post-exposure protection studies. Vaccine 1985, 3, 325-332.
15. Jallet, C., Jacob, Y., Bahloul, C., Drings, A. et al., Chimeric lyssavirus glycoproteins with increased immunological potential. J. Virol. 1999, 73, 225-233.
16. Lodmell, D. L., Esposito, J. J., Ewalt, L. C., Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals. Vaccine 2004, 22, 3329-3333.
17. Perrin, P, Joffret, M.-L., Oth, D., Leclerc, C., Sureau, P., Thibodeau, L., Interleukin 2 production in vitro: a new approach to the study of rabies vaccine immunogenicity as appraised by testing different glycoprotein presentations. Vaccine 1988, 6, 331-338.
18. Prehaud, C., Takehara, K., Flamand, A., Bishop, D. H., Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors. Virology 1989, 173, 390-399.
19. Tordo, N., Bourhy, H., Sather, S., Ollo, R., Structure and expression in baculovirus of Mokola virus glycoprotein: an efficient recombinant vaccine. Virology 1993, 194, 59-69.
20. Ivey-Hoyle, M., Recombinant gene expression in cultured Drosophila melanogaster cells. Curr. Opin. Biotechnol. 1991, 2, 704-707.
21. Ikonomou, L., Schneider, Y.-J., Agathos, S. N., Insect cell culture for industrial production of recombinant proteins. Appl. Microbiol. Biotechnol. 2003, 62, 1-20.
22. Chomczynski, P., Sacchi, N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem, 1987, 162, 156-159.
23. Perrin, P., Lafon, M., Sureau, P., Enzyme linked immuno-sorbent assay (ELISA) for the determination of glycoprotein content of rabies vaccines, in: Meslin, F X, Kaplan, M. M, Koprowaski, H, (Eds), Laboratory Techniques in Rabies, WHO, Geneva 1996, pp. 383-388.
24. Drings, A., Jallet, C., Chambert, B., Tordo, N., Perrin, P., Is there an advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine? Vaccine 1999, 17, 1549-1557.
25. Pinto, R., Bosh, A., Bishop, D., Structures associated with the expression of rabies virus structural genes in insect cells. Virus Res. 1994, 31, 139-145.
26. Tuchiya, K., Matsuura, Y., Kawai, A., Ishihama A., Ueda, S., Characterization of rabies virus glycoprotein expressed by recombinant baculovirus. Virus Res. 1992, 25, 1-13.
27. Brillet, K., Conceição, M. M., Pattus, F, Pereira, C. A., Bioprocess parameters of cell growth and human mu opioid receptor expression in recombinant Drosophila S2 cell cultures in a bioreactor. Bioprocess Biosyst. Eng. 2006, 28, 291-293.
28. Zanetti, C. R., Tinno de Franco, M., Vassão, R. C., Pereira, C. A., Pereira, O. A. C., Failure of protection induced by vaccination in cross protection experimental studies with Brazilian wild strains of rabies viruses. Arch. Virol. 1998, 143, 1745-1756.
29. Lodmell, D. L., Smith, J. S., Esposito, J. J., Ewalt, L. C., Cross-protection of mice against a global spectrum of rabies virus variants. J. Virol. 1995, 69, 4957-4962.